NYBSP-1

General Information


DRACP ID  DRACP04382

Peptide Name   NYBSP-1

Sequence  TIEEQAKTⓍLDKⓍNHEAEDLFYQⓍSLAⓍWN

Sequence Length  30

UniProt ID  Q9BYF1 

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Cancer targeted peptides Stapled Peptides



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
HT1080/ACE2 Fibrosarcoma Sarcoma CC50>27.5 μM MTS assay 24 h 1
A549/ACE2 Lung adenocarcinoma Carcinoma CC50>27.5 μM MTS assay 24 h 1

Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antiviral



Structure Information


PDB ID  Not available

Predicted Structure  Not available

Helicity  94

Linear/Cyclic  Cyclic (Stapled)

Disulfide/Other Bond  Stapled: Ⓧ(9) and Ⓧ (13), Ⓧ(24) and Ⓧ (28) are cross-linked by hydrocarbon stapling

N-terminal Modification  Acetylation

C-terminal Modification  Amidation

Other Modification  Ⓧ=S-2-(4-pentenyl) alanine

Chiral  L



Physicochemical Information


Formula  C137H197N35O43

Absent amino acids  CGMPRV

Common amino acids  E

Mass  353974

Pl  4.1

Basic residues  3

Acidic residues  6

Hydrophobic residues  9

Net charge  -3

Boman Index  -6306

Hydrophobicity  -87.67

Aliphatic Index  62

Half Life 
  /

Extinction Coefficient cystines  6990

Absorbance 280nm  241.03

Polar residues  6

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 33310780

Title  Stapled Peptides Based on Human Angiotensin-Converting Enzyme 2 (ACE2) Potently Inhibit SARS-CoV-2 Infection In Vitro

Doi Not available

Year  2020

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  19262

DRACP is developed by Dr.Zheng's team.